Literature DB >> 20068076

MicroRNA expression differentiates histology and predicts survival of lung cancer.

Maria Teresa Landi1, Yingdong Zhao, Melissa Rotunno, Jill Koshiol, Hui Liu, Andrew W Bergen, Maurizia Rubagotti, Alisa M Goldstein, Ilona Linnoila, Francesco M Marincola, Margaret A Tucker, Pier Alberto Bertazzi, Angela C Pesatori, Neil E Caporaso, Lisa M McShane, Ena Wang.   

Abstract

PURPOSE: The molecular drivers that determine histology in lung cancer are largely unknown. We investigated whether microRNA (miR) expression profiles can differentiate histologic subtypes and predict survival for non-small cell lung cancer. EXPERIMENTAL
DESIGN: We analyzed miR expression in 165 adenocarcinoma and 125 squamous cell carcinoma (SQ) tissue samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study using a custom oligo array with 440 human mature antisense miRs. We compared miR expression profiles using t tests and F tests and accounted for multiple testing using global permutation tests. We assessed the association of miR expression with tobacco smoking using Spearman correlation coefficients and linear regression models, and with clinical outcome using log-rank tests, Cox proportional hazards, and survival risk prediction models, accounting for demographic and tumor characteristics.
RESULTS: MiR expression profiles strongly differed between adenocarcinoma and SQ (P(global) < 0.0001), particularly in the early stages, and included miRs located on chromosome loci most often altered in lung cancer (e.g., 3p21-22). Most miRs, including all members of the let-7 family, were downregulated in SQ. Major findings were confirmed by quantitative real time-polymerase chain reaction (qRT-PCR) in EAGLE samples and in an independent set of lung cancer cases. In SQ, the low expression of miRs that are downregulated in the histology comparison was associated with 1.2- to 3.6-fold increased mortality risk. A five-miR signature significantly predicted survival for SQ.
CONCLUSIONS: We identified a miR expression profile that strongly differentiated adenocarcinoma from SQ and had prognostic implications. These findings may lead to histology-based therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068076      PMCID: PMC3163170          DOI: 10.1158/1078-0432.CCR-09-1736

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

Review 1.  Control of translation and mRNA degradation by miRNAs and siRNAs.

Authors:  Marco Antonio Valencia-Sanchez; Jidong Liu; Gregory J Hannon; Roy Parker
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

2.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples.

Authors:  Yaguang Xi; Go Nakajima; Elaine Gavin; Chris G Morris; Kenji Kudo; Kazuhiko Hayashi; Jingfang Ju
Journal:  RNA       Date:  2007-08-13       Impact factor: 4.942

3.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

4.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

Review 5.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.

Authors:  Hisayuki Shigematsu; Adi F Gazdar
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

6.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Authors:  Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Authors:  Elena Gallardo; Alfons Navarro; Nuria Viñolas; Ramon M Marrades; Tania Diaz; Bernat Gel; Angels Quera; Eva Bandres; Jesus Garcia-Foncillas; Jose Ramirez; Mariano Monzo
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

9.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Authors:  Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

10.  miRBase: microRNA sequences, targets and gene nomenclature.

Authors:  Sam Griffiths-Jones; Russell J Grocock; Stijn van Dongen; Alex Bateman; Anton J Enright
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  157 in total

1.  The role of postmortem studies in pneumonia etiology research.

Authors:  Gareth D H Turner; Charatdao Bunthi; Chizoba B Wonodi; Susan C Morpeth; Catherine S Molyneux; Sherif R Zaki; Orin S Levine; David R Murdoch; J Anthony G Scott
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

Review 2.  Should we continue to use the term non-small-cell lung cancer?

Authors:  A F Gazdar
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

3.  Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.

Authors:  Sweta Rani; Kathy Gately; John Crown; Ken O'Byrne; Lorraine O'Driscoll
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

Review 4.  Involvement of microRNAs in lung cancer biology and therapy.

Authors:  Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

5.  MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

Authors:  Johannes Voortman; Akiteru Goto; Jean Mendiboure; Jane J Sohn; Aaron J Schetter; Motonobu Saito; Ariane Dunant; Trung C Pham; Iacopo Petrini; Alan Lee; Mohammed A Khan; Pierre Hainaut; Jean-Pierre Pignon; Elisabeth Brambilla; Helmut H Popper; Martin Filipits; Curtis C Harris; Giuseppe Giaccone
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

6.  Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data.

Authors:  Masih Sherafatian; Fateme Arjmand
Journal:  Oncol Lett       Date:  2019-06-10       Impact factor: 2.967

7.  Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues.

Authors:  Tram K Lam; Stephanie Shao; Yingdong Zhao; Francesco Marincola; Angela Pesatori; Pier Alberto Bertazzi; Neil E Caporaso; Ena Wang; Maria Teresa Landi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

8.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 9.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

10.  Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.

Authors:  Klaudia Skrzypek; Magdalena Tertil; Slawomir Golda; Maciej Ciesla; Kazimierz Weglarczyk; Guillaume Collet; Alan Guichard; Magdalena Kozakowska; Jorge Boczkowski; Halina Was; Tomasz Gil; Jaroslaw Kuzdzal; Lucie Muchova; Libor Vitek; Agnieszka Loboda; Alicja Jozkowicz; Claudine Kieda; Jozef Dulak
Journal:  Antioxid Redox Signal       Date:  2013-06-27       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.